RAPID: Rapamycin for Alzheimer´s Prevention in Individuals at-Risk for Cognitive Decline
Description: The purpose of this project is to plan a multicentre randomized controlled trial (RAPID) to evaluate whether the mTOR inhibitor rapamycin can prevent neurodegenerative progression in individuals at increased risk for dementia. The aim is to finalize trial design, regulatory documentation, recruitment infrastructure, and statistical analysis plans, enabling a full clinical study application within two years.Rapamycin has shown consistent benefits in Alzheimer’s disease (AD) mouse models, preventing or reversing amyloid and tau pathology, cerebral hypometabolism, and vascular dysfunction. Despite strong preclinical support, human evaluation remains limited. Our pilot trial (ERAP, n=13, early-stage AD, 6 months) demonstrated feasibility of recruitment, regulatory approval, imaging, CSF sampling, and safety monitoring, supporting further investigation in a larger trial.RAPID will target individuals aged 60-79 with subjective cognitive decline and elevated dementia risk. The trial will be 24 months, placebo-controlled, double-blind, with a change in cognitive scores as the primary endpoint, complemented by CSF and imaging biomarkers.This planning project will establish collaborations with memory clinics across at least five Swedish regions, finalize agreements with a contract research organization, and set up an advisory board with user representatives. The outcome will be a ready-to-launch protocol addressing a major unmet need: pharmacological prevention of dementia.
Funder: Vetenskapsrådet
Amount: SEK 1,200,000
Funding type: research
Funder scheme: Project grant
Start date: 2026-01-01
End date: 2026-12-31
Investigator: Jonas Svensson (lead)
Institutions: Region Stockholm, Stockholm county council
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Funded outputs count: 0
Funder award ID: 2025-07430
OpenAlex ID: G331734263
